Pulmonary Hypertension KOL Interview – Germany
Pulmonary Hypertension KOL Interview – Germany
$599.00
This interview with a Germany-based key opinion leader (KOL) provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Uptravi, Opsumit, Tyvaso, Remodulin (and Remunity), Adcirca, INOpulse, and sotatercept.
Publisher: Biomedtracker
- Highlights
- Description
Highlights
You know there is no approved treatment for group 2 and 3 PH, so some of these patients with severe PH are being treated, and there is a very clear preference for PDE5 inhibitors around the world. When it comes to group 4, of course it is the approved drug globally, riociguat, so that’s the preferred treatment there although in many countries it is not reimbursed and PDE5 inhibitors are used quite frequently. The preferred treatment for group 1 PH or PAH is a combination therapy of PDE5 inhibitors and ERA.
We tend to believe that compliance is high among patients with PH because they know that they have a severe disease, they usually benefit from the drugs, so they feel better, which is important of course, and the drugs are usually well-tolerated. So, we as a group, believe that the compliance rate is higher than 80%, but no one knows for sure.
Overview
This interview with a Germany-based key opinion leader (KOL) provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Uptravi, Opsumit, Tyvaso, Remodulin (and Remunity), Adcirca, INOpulse, and sotatercept.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Pulmonary Hypertension KOL Interview – France 
Sign up to the